582 related articles for article (PubMed ID: 26833127)
41. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.
Shen X; Zhao Y; Liu G; Zhou HL; Fan J; Zhang L; Li YL; Wang Y; Liang J; Xu ZX
Life Sci; 2020 Sep; 256():117923. PubMed ID: 32522567
[TBL] [Abstract][Full Text] [Related]
42. Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain.
Sobottka SB; Haase M; Fitze G; Hahn M; Schackert HK; Schackert G
J Neurooncol; 2000 Sep; 49(3):187-95. PubMed ID: 11212897
[TBL] [Abstract][Full Text] [Related]
43. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
[TBL] [Abstract][Full Text] [Related]
44. Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene.
Carretero J; Medina PP; Pio R; Montuenga LM; Sanchez-Cespedes M
Oncogene; 2004 May; 23(22):4037-40. PubMed ID: 15021901
[TBL] [Abstract][Full Text] [Related]
45. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.
Liu Y; Marks K; Cowley GS; Carretero J; Liu Q; Nieland TJ; Xu C; Cohoon TJ; Gao P; Zhang Y; Chen Z; Altabef AB; Tchaicha JH; Wang X; Choe S; Driggers EM; Zhang J; Bailey ST; Sharpless NE; Hayes DN; Patel NM; Janne PA; Bardeesy N; Engelman JA; Manning BD; Shaw RJ; Asara JM; Scully R; Kimmelman A; Byers LA; Gibbons DL; Wistuba II; Heymach JV; Kwiatkowski DJ; Kim WY; Kung AL; Gray NS; Root DE; Cantley LC; Wong KK
Cancer Discov; 2013 Aug; 3(8):870-9. PubMed ID: 23715154
[TBL] [Abstract][Full Text] [Related]
46. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
[TBL] [Abstract][Full Text] [Related]
47. Serine threonine kinase 11/liver kinase B1 mutation in sporadic scirrhous-type gastric cancer cells.
Nishimura S; Yashiro M; Sera T; Yamamoto Y; Kushitani Y; Sugimoto A; Kushiyama S; Togano S; Kuroda K; Okuno T; Murakami Y; Ohira M
Carcinogenesis; 2020 Nov; 41(11):1616-1623. PubMed ID: 32236518
[TBL] [Abstract][Full Text] [Related]
48. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
49. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.
Chen Z; Li JL; Lin S; Cao C; Gimbrone NT; Yang R; Fu DA; Carper MB; Haura EB; Schabath MB; Lu J; Amelio AL; Cress WD; Kaye FJ; Wu L
J Clin Invest; 2016 Jun; 126(6):2267-79. PubMed ID: 27140397
[TBL] [Abstract][Full Text] [Related]
50. A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma.
Qiu W; Schönleben F; Thaker HM; Goggins M; Su GH
Oncogene; 2006 May; 25(20):2937-42. PubMed ID: 16407837
[TBL] [Abstract][Full Text] [Related]
51. LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors.
Caiola E; Iezzi A; Tomanelli M; Bonaldi E; Scagliotti A; Colombo M; Guffanti F; Micotti E; Garassino MC; Minoli L; Scanziani E; Broggini M; Marabese M
J Thorac Oncol; 2020 Mar; 15(3):360-370. PubMed ID: 31634668
[TBL] [Abstract][Full Text] [Related]
52. BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer.
Rodriguez-Nieto S; Sanchez-Cespedes M
Carcinogenesis; 2009 Apr; 30(4):547-54. PubMed ID: 19176640
[TBL] [Abstract][Full Text] [Related]
53. Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.
Pécuchet N; Laurent-Puig P; Mansuet-Lupo A; Legras A; Alifano M; Pallier K; Didelot A; Gibault L; Danel C; Just PA; Riquet M; Le Pimpec-Barthes F; Damotte D; Fabre E; Blons H
Oncotarget; 2017 Apr; 8(14):23831-23840. PubMed ID: 26625312
[TBL] [Abstract][Full Text] [Related]
54. STK11 mutation impacts CD1E expression to regulate the differentiation of macrophages in lung adenocarcinoma.
Zhang Q; Feng J; Liu K; Yang X; Huang Y; Tang B
Immun Inflamm Dis; 2023 Jul; 11(7):e958. PubMed ID: 37506141
[TBL] [Abstract][Full Text] [Related]
55. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
56. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
57. Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation.
Wang H; Guo J; Shang X; Wang Z
Int Immunopharmacol; 2020 Jul; 84():106574. PubMed ID: 32413741
[TBL] [Abstract][Full Text] [Related]
58. YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin.
Zhang W; Gao Y; Li F; Tong X; Ren Y; Han X; Yao S; Long F; Yang Z; Fan H; Zhang L; Ji H
Cancer Res; 2015 Nov; 75(21):4450-7. PubMed ID: 26363011
[TBL] [Abstract][Full Text] [Related]
59. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
[TBL] [Abstract][Full Text] [Related]
60. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in
Adeegbe DO; Liu S; Hattersley MM; Bowden M; Zhou CW; Li S; Vlahos R; Grondine M; Dolgalev I; Ivanova EV; Quinn MM; Gao P; Hammerman PS; Bradner JE; Diehl JA; Rustgi AK; Bass AJ; Tsirigos A; Freeman GJ; Chen H; Wong KK
Cancer Immunol Res; 2018 Oct; 6(10):1234-1245. PubMed ID: 30087114
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
